Superworth

Definium Therapeutics price to book ratio DFTX

Market value divided by the book value of the company's net assets, since 2022.

Today, Nov 2, 2026
4.7×
5-year median
2.2×
Against its 5-year history
73rd
percentile: 0 is its lowest day, 100 its highest
5-year range
0.5× to 18.4×
Peer median
3.3×

Definium Therapeutics' price to book ratio is 4.7× as of Nov 2, 2026.

That is above its 5-year median of 2.2×, higher than on 73% of days in the last 5 years.

Over that time it ranged from 0.5× in Dec 2022 to 18.4× in Jul 2026.

The median for 10 chemicals stocks of a similar size is 3.3×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far4.7×4.7×18.4×
20259.9×1.7×9.9×
20241.9×1.5×5.8×
20231.5×0.6×1.6×
20220.5×0.5×3.2×

Against its peers

Companies in Chemicals nearest Definium Therapeutics' size, closest first, today.

CompanyPrice to book ratio
DFTXDefinium Therapeutics4.7×
AVNTAvient1.6×
CSWCSW Industrials4.2×
CBTCabot2.4×
BCPCBalchem4.2×
WDFCWD 4011.2×
HXLHexcel4.7×
FULFuller H B1.3×
NGVTIngevity54.0×
IOSPInnospec1.8×
EMNEastman Chemical1.3×
Peer median3.3×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Definium Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.